Tongli Pharmaceuticals (USA) Signed New Distribution Agreement With Shandong Shanglian Biochemical Medicine Limited Company
Published: Mar 22, 2011
HARBIN, China, March 22, 2011 /PRNewswire/ -- Tongli Pharmaceuticals (USA) Inc. (OTC Bulletin Board: TGLP), announced today that the company signed new distribution agreement with Shandong Shanglian Biochemical Medicine Limited Company. Five of our products including Antihyperlipidemics, Calcium Gluconate Oral Liquid, Panax and Radix Polygoni Capsule, Metformin Hydrochloride Tablets, Clindamycin Hydrochloride will be sold at four cities (Zibo, Weifang, Linyi and Liaocheng) of Shandong Province. As of 2010, the total sales of medicine industry in these four cities was RMB 40 Billion ($6 Billion). This is the first time that our products will be sold in Shandong Province. Company expects it a positive factor in boosting the company's revenue in 2011 significantly.
Mr. Mingli Yao, Chairman and CEO commented, "We're happy to have the great opportunity to cooperate with Shandong Shanglian Biochemical Medicine Limited Company. We feel this reflects a growing interest in our company based on our continued ability to implement our business strategies and drive Tongli's revenues and profits. We expect our products will be sold to more cities in Shandong Province in the near future."
About Tongli Pharmaceuticals (USA) Inc.
Tongli Pharmaceuticals (USA) Inc. is a pharmaceutical company located in Harbin, China. The Company's manufacturing facilities are GMP certified in China, engaged in producing a range of prescription and over-the-counter products.
About Shandong Shanglian Biochemical Medicine Limited Company.
Shandong Shanglian Biochemical Medicine Limited Company is one of the largest medicine wholesale and retail companies in Shandong Province. It has thousands of chain stores and retail stores all over the Shandong Province.
Cautionary Note Regarding Forward Looking Statements
Statements made in this press release that are not of historical in nature are forward-looking and are pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
SOURCE Tongli Pharmaceuticals (USA) Inc.